



7th December 2009

NORGINE WINS KEY AWARD

- **judges include Welsh Assembly, industry and academia**



From left to right: Martin McHugh, Zarlink Semiconductor (last years winner) Gaynor Mollaney, Norgine's Site Quality Director and Roger Jones Site Director, Norgine.

Leading European specialty pharma group Norgine has won the esteemed Judges' Award at the 2009 MediWales Innovation Awards, recognising and celebrating some of the best performers in the Welsh healthcare sector (MediWales.com).

The company recently announced that 2008 had marked 22 consecutive years of double-digital sales growth (at constant exchange rates), an achievement that was

acknowledged at MediWales this year by a prestigious judging panel comprising sector specialists from the Welsh Assembly (life sciences team), representatives from industry, MediWales directors and medical academia.

"The Judges' award is presented to the entry that, while not receiving a specific category award, is felt to best represent the spirit of the awards – an entry that demonstrates advancement which should be recognised and celebrated as a credit to the sector," said Debbie Laubach, Project Manager at MediWales. "The judges wanted to give Norgine recognition for its continuous growth, which really deserved celebrating."

The company's total revenue increased to €240.8m in 2008, with net product sales increasing by 5% to €232.8m. On a constant currency basis, net product sales increased by just over 10% – enabling the group to deliver double-digit sales growth without break for more than two decades.

Peter Stein, CEO, said: "In today's tough economic climate, our continued investment in development programmes and in improving our business skills, quality standards and compliance to the highest industry standards has paid dividends."

Norgine has a manufacturing facility in Hengoed, Wales, from which it supplies markets in Europe, the USA, Australasia and Africa..

ENDS

Notes to Editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a direct presence in all the major European markets. In 2008, Norgine celebrated its 22nd year of double-digit net product sales growth at constant exchange rates. The company employs over 1,000 people. Norgine is focused on developing and marketing pharmaceutical products that address significant unmet clinical needs in gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas: eg, MOVICOL[®] for the treatment of constipation and faecal impaction, MOVIPREP[®] a new generation of bowel cleansing preparation, KLEAN-PREP[®] for bowel preparation prior to colonoscopy, XIFAXAN[®] for the treatment of traveller's diarrhoea, FIVASA[®] for the treatment of ulcerative colitis and Crohn's disease and ORAMORPH[®] for the treatment of moderate-to-severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, Wales and Dreux in France.

For further information, please contact:

Julie Hornby Winfield: Global Corporate Communications Manager
T: +44 (0)1895 826642

E: jhornbywinfield@norgine.com

Norgine's website www.norgine.com

Rob Skelding

Euro RSCG Life Medicom

www.medicomgroup.com

2009 PMEA Public Health Marketing Award

2009 PMEA Medical Devices Marketing Award

2008 Communiqué Medical Education Consultancy of the Year

2008 PharmaTimes Marketing Consultancy of the Year

T: +44 (0)208 481 8138

M: +44 (0)7788 723707

The Medicom Group of companies is part of Euro RSCG Life

Thameside House, Hurst Road, Hampton Court, Surrey KT8 9AY, UK. Fax +44 (0)208 481 8105

Medicom Group is the trade name Euro RSCG Life Medicom and is registered in England. Registration Number 4675702. Euro RSCG Life Medicom or any of its subsidiary companies may not be held responsible for the content of this email as it may reflect the personal view of the sender and not that of the company. This e-mail and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the sender by replying to the e-mail containing this attachment. Replies to this email may be monitored for operational or business reasons. Whilst every endeavour is taken to ensure that e-mails are free from viruses, no liability can be accepted and the recipient is requested to use their own virus checking software.
